The U.S. Food and Drug Administration (FDA) has granted clearance to DermaSensor Inc., a pioneer in non-invasive skin cancer evaluation tools, making it the first AI-powered medical device approved for detecting all three of the most common skin cancers (melanoma, basal cell carcinoma, and squamous cell carcinoma). This innovation comes as a significant advancement in the realm of primary care, offering 300,000 primary care physicians (PCPs) across the country the ability to perform quantitative, point-of-care tests for skin cancer, thus expediting patient access to critical care.
In the United States, skin cancer is a prevalent concern, with one out of five Americans expected to experience this condition by the age of 70. The cost for treating skin cancers is substantial—approximately $8.1 billion annually. Early detection is key, as 99 percent of skin cancers, including melanoma, are curable when caught early. Due to limited access to dermatology, especially in rural areas, the empowerment of primary care facilities to identify referral-worthy cases is now more crucial than ever.
Typically, PCPs have relied on visual inspection, using either the naked eye or magnified examination, to evaluate suspicious moles, a process heavily dependent on clinical expertise and subjective assessment. DermaSensor’s cutting-edge AI technology, however, now allows for non-invasive analysis of cellular and subcellular features in lesions, providing immediate and objective results from its FDA-cleared algorithm through a wireless, handheld device.
The effectiveness of the DermaSensor unit has been substantiated by a comprehensive FDA pivotal study involving over 1,000 patients, with leadership from the Mayo Clinic and participation from 22 study centers. Results from this study indicated an impressive 96 percent sensitivity across the 224 identified skin cancers. Further, the device demonstrated a 97 percent likelihood of correctly identifying benign results across all skin cancer types. In an additional clinical utility study involving 108 physicians, the device was seen to halve the number of missed skin cancers, enhancing diagnostic accuracy and confidence among primary care physicians.
Co-founder and CEO Cody Simmons of DermaSensor expressed enthusiasm about the role of AI in healthcare moving forward, especially when coupled with novel technologies like spectroscopy. He underscored the significant gap that has now been bridged in equipping PCPs to evaluate skin cancer. This milestone is also poised to benefit dermatologists by fostering better collaboration with primary care and ensuring more efficient referrals, ultimately ensuring quicker treatment for patients with skin cancer.
With a devoted 12-year research and development effort, backed by tens of millions of dollars in investment, the journey of DermaSensor to achieve FDA clearance has been monumental. Dr. Maurice Ferre, the co-founder and chairman, highlighted the company’s gratitude towards the FDA’s cooperation since their initial pre-submission meeting in 2016 and their subsequent FDA-Breakthrough Designated De Novo submission.
DermaSensor’s journey to FDA clearance has been supported by 13 clinical studies over the last decade, with six principal studies significantly contributing to the FDA’s approval. The clearance heralds a new era for primary care physicians and dermatologists to identify and treat skin cancer more effectively, potentially revolutionizing the management of the most common form of cancer in the United States.
With DermaSensor’s groundbreaking device now cleared by the FDA, the future of skin cancer detection and treatment in primary care settings looks both hopeful and increasingly proactive in providing early and potentially life-saving interventions.
